We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.71B
AUM Growth
+$23.5M
Cap. Flow
+$140M
Cap. Flow %
8.18%
Top 10 Hldgs %
56.71%
Holding
87
New
17
Increased
22
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$30M
2
XNCR icon
Xencor
XNCR
+$20.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20M
4
GH icon
Guardant Health
GH
+$19.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$17M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.8M
2
UTHR icon
United Therapeutics
UTHR
+$18.1M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$15.8M
4
ZTS icon
Zoetis
ZTS
+$14.8M
5
EXEL icon
Exelixis
EXEL
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
51
Adicet Bio
ACET
$75.3M
$5.44M 0.32%
+19,437
New +$3.34M
PTCT icon
52
PTC Therapeutics
PTCT
$6.29B
$5.28M 0.31%
132,448
-97,571
-42% -$3.73M
KURA icon
53
Kura Oncology
KURA
$901M
$5.17M 0.3%
369,173
-385,948
-51% -$6.25M
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.62M 0.27%
212,281
+5,717
+3% +$126K
AXSM icon
55
PUT
Axsome Therapeutics
AXSM
$12.3B
$3.78M 0.22%
+100,000
New +$3.68M
NVCR icon
56
CALL
NovoCure
NVCR
$1.97B
$3.75M 0.22%
50,000
+20,000
+67% +$2.01M
ITCI
57
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.98M 0.17%
56,915
-170,504
-75% -$7.16M
KURA icon
58
CALL
Kura Oncology
KURA
$901M
$2.45M 0.14%
+175,000
New +$2.84M
ICPT
59
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.45M 0.14%
150,400
-39,600
-21% -$668K
CYT
60
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$2.04M 0.12%
179,450
-66,871
-27% -$1.02M
MRNS
61
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.04M 0.12%
171,338
+4,627
+3% +$53.4K
INKT icon
62
MiNK Therapeutics
INKT
$52.8M
$1.54M 0.09%
+34,550
New +$4.11M
ALGS icon
63
Aligos Therapeutics
ALGS
$25.2M
$1.52M 0.09%
5,112
+138
+3% +$50.3K
SYBX
64
DELISTED
Synlogic
SYBX
$1.39M 0.08%
38,331
– –
PDSB icon
65
PDS Biotechnology
PDSB
$38.7M
$1.16M 0.07%
142,635
– –
FUSN
66
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$326K 0.02%
78,066
– –
PODD icon
67
Insulet
PODD
$11.4B
$284K 0.02%
1,066
– –
EW icon
68
Edwards Lifesciences
EW
$47.8B
$182K 0.01%
+1,406
New +$164K
ALXO icon
69
ALX Oncology
ALXO
$272M
– –
-107,220
Closed -$7.92M
AMRN
70
Amarin Corp
AMRN
$290M
– –
-53,498
Closed -$5.46M
AZN icon
71
AstraZeneca
AZN
$263B
– –
-564,136
Closed -$67.8M
BIIB icon
72
Biogen
BIIB
$29.5B
– –
-33,220
Closed -$9.4M
BMY icon
73
CALL
Bristol-Myers Squibb
BMY
$128B
– –
-400,000
Closed -$23.7M
EXEL icon
74
Exelixis
EXEL
$14B
– –
-488,414
Closed -$10.3M
MRK icon
75
CALL
Merck
MRK
$323B
– –
-600,000
Closed -$45.1M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Sofinnova Investments held 87 positions worth $1.71B, up 1.4% from $1.69B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $140M of net new capital in Q4 2021, opening 17 new positions and adding to 22 existing holdings. Its largest new stake was Xencor: 537,030 shares worth $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $18.1M trimmed.

  • Sofinnova Investments's largest Q4 2021 buy was Xencor: 537,030 shares worth $21.5M.
  • Sofinnova Investments added most to Regenxbio in Q4 2021, an estimated $30M increase.
  • Sofinnova Investments's biggest Q4 2021 reduction was United Therapeutics, cutting an estimated $18.1M.
  • Sofinnova Investments fully exited AstraZeneca in Q4 2021, selling an estimated $67.8M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.71B portfolio in Q4 2021.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q4 2021.
  • Sofinnova Investments's portfolio value rose 1.4% quarter-over-quarter to $1.71B.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.